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The efficacy of T cells depends on their functional avidity, i. e., the strength of T cell
interaction with cells presenting cognate antigen. The overall T cell response is composed
of multiple T cell clonotypes, involving different T cell receptors and variable levels of
functional avidity. Recently, it has been proposed that the presence of low avidity tumor
antigen-specific CD8T cells hinder their high avidity counterparts to protect from tumor
growth. Here we analyzed human cytotoxic CD8T cells specific for themelanoma antigen
Melan-A/MART-1. We found that the presence of low avidity T cells did not result in
reduced cytotoxicity of tumor cells, nor reduced cytokine production, by high avidity T
cells. In vivo in NSG-HLA-A2 mice, the anti-tumor effect of high avidity T cells was similar
in presence or absence of low avidity T cells. These data indicate that low avidity T cells
are not hindering anti-tumor T cell responses, a finding that is reassuring because low
avidity T cells are an integrated part of natural T cell responses.
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INTRODUCTION
The strength of the interaction between T cells and antigen-bearing cells depends on the TCR
affinity to peptide-MHC, and on multiple co-receptors that together determine the overall binding
kinetic and consequent signaling into T cells. The multiple receptor-ligand pairs are organized in
the highly complex immune synapse. Many studies have provided great insight into the structure
and function of the synapse (1, 2). However, structural data are not sufficient to calculate or
predict the function outcome. Therefore, cellular functional assays are still of central importance for
assessing the strength that is to say the “functional avidity,” of T cell interactions and their functional
consequence in vitro and in vivo, including the net overall outcome of the T cell response (3, 4).
Standard methods to determine the functionality avidity (hereafter abbreviated with “avidity”) are
cytotoxicity or IFN-γ Elispot assays with titrated concentrations of antigenic peptide. The peptide
concentration that mediates half-maximal activity is called EC50 and used as avidity measure (5, 6).
High and low avidity T cells seem to participate both in immune responses against tumors in
humans and animals. There is a consensus that higher avidity T cells contribute more strongly to
immunity as opposed to lower avidity T cells (7–10). Whether or not they act synergistically is less
well-known. It has been reported that chronic antigen exposure may tolerize T cells whereby the
degree of tolerization may differ depending on the T cell’s avidity (11, 12).
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It is challenging to determine the net contribution of
individual T cell clonotypes to immunity (i.e., to the disease
outcome). The best experimental method consists of the
transfer of defined T cell populations to individuals bearing an
infection or a tumor, and to quantify the consequent immune
protection. This procedure is straightforward for murine studies.
For humans the possibilities are limited. However, adoptive
T cell therapy (ACT) is increasingly performed, for example
for the treatment of patients with metastatic melanoma. This
technique relies on the isolation of autologous tumor-infiltrating
lymphocytes (TILs) from tumor biopsies or CD8T cell clones
derived from peripheral blood T cells that are expanded and re-
injected into patients, with the aim that these TILs/CD8T cells
then directly kill tumor cells (13, 14). Even though technically
and clinically challenging, TIL-ACT showed promising results
in terms of objective clinical responses and durability of
responses (15–17).
Despite these clinical successes, ACT has limitations in
availability and generation of therapeutic tumor-reactive T cells
of sufficiently high avidity for a larger group of patients.
Traditionally, generating or selecting high avidity TILs in
vitro include MHC/antigen tetramer staining and sorting, with
stronger tetramer binding indicative of higher avidity and
tumor reactivity (8, 18). Alternatively, T cells can also be
expanded in vitro in the presence of low concentrations of
peptide, which selects for T cells with higher avidity and
greater tumor reactivity (19). Nevertheless, its widespread
application is hindered by the laborious nature and limited
success rate of isolating and expanding TILs for patient
treatment. To overcome this disadvantage, peripheral T cells
can be genetically engineered to express TCRs or chimeric
antigen receptors with a high avidity and excellent specificity
for target antigen, as well as costimulatory molecules that
provide the T cells with enhanced properties required for
effective ACT therapy (20, 21). Several studies have shown
measurable success of genetically modified T cells in melanoma
FIGURE 1 | Cytotoxicity by T cell clones, alone and in mixed cultures of high and low avidity clones. (A) Peptide (Melan-A peptide EAAGIGILTV; “EAA”), titration curves
in an IFN-γ Elispot assay, to determine the functional avidity of the clones used for the subsequent killing assays. (B) The low avidity clone 93 did not inhibit the lysis of
melanoma cells by the high avidity clone 211. (C) Average ± standard deviation, and statistical comparisons (One-way Anova) of four independent cytotoxicity assays
at the E:T ratio of 30:1, using the clones described in Table 1. P-values **<0.01; *<0.05. No peptide was added in (B,C); tumor cell recognition was based on
endogenous expression of Melan-A by the Me290 melanoma target cells. Ratio E:T; effector to target cell ratio.
patients (22, 23), but they also demonstrated the occurrence of
unexpected toxicities.
Considering the co-existence of high and low avidity T cells
within tumors, we thought it is worthwhile to determine whether
the presence of low avidity T cells in our experimental systems
in vitro and in vivo would hinder the high avidity T cells in their
activities against melanoma. Therefore, we compared the T cell’s
function in experiments using T cell clones with defined avidity,
by using them individually and in parallel to mixtures of T cell
cones with different avidities.
RESULTS
Similar Killing of Melanoma Cells by High
Avidity Cytotoxic T Cells in Presence or
Absence of Low Avidity T Cells
For the analysis of human CD8T cell responses with different
avidities, we generated T cell clones from HLA-A∗02:01
melanoma patients and determined their functional avidity
(Figure 1A and Table 1) as described previously (3, 24).
Subsequently, we determined the cytotoxicity and found that the
low avidity clones showed lower killing of Me290 melanoma cells
as compared to the high avidity clones (Figure 1B). Then we
used these clones to ask the question whether the low avidity
clone could influence the function of the more efficient clones.
We found that the presence of the low avidity T cell clone 93
did not hinder the cytotoxicity of the high avidity clone 211
when they were mixed together (Figure 1B). The killing by the
mixed T cells was slightly lower which may have been due to the
fact that these wells contained only half the number of the high
affinity clone than in the conditions with only a single clone, since
the remaining cells of the mix were the low avidity T cells. The
compiled data from four independent experiments show that the
differences were statistically significant, i.e., that the low avidity
clones indeed exerted weaker killing as compared to the mixed
clones as in comparison to the high avidity clones (Figure 1C).
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TABLE 1 | Overview of the CD8T cell clones used in this study.
Clone Patient (Lau) Functional
avidity group
Elispot EC50 (M) R square
201 975 High 1.80E-12 0.9533
211 1,013 High 1.86E-12 0.9428
212 1,013 High 7.13E-11 0.9687
214 1,013 High 2.71E-10 0.9708
93 944 Low 2.48E-10 0.9840
95 944 Low 2.0E-10 N/A
33 618 Low 1.28E-09 0.9643
35 618 Low 5.49E-09 0.9455
All clones are specific for Melan-A/HLA-A2. They were generated from patient’s PBMC
as described in Material and Methods. IFN-γ Elispot assays with titrated Melan-A peptide
were performed to determine the peptide concentration at half maximal activity (EC50),
reflecting the functional avidity. Low avidity clones are considered the ones having an
EC50 above 2.50E-10 (M). The R square values represent the goodness of sigmoid curve
fit. As an exception, the functional avidity of clone 95 was determined using a cytotoxicity
assay, in contrast to all other clones for which the functional avidity was determined by
IFN-γ Elispot assays. We have previously shown that the two assays generate similar
results (3).
Pre-incubation of Melanoma Cells With
Low Avidity T Cells Does Not Reduce Their
Susceptibility to Lysis
Next, we assessed if pre-incubation of the low avidity T cells
could reduce the subsequent susceptibility of target cells to high
avidity cytotoxic T cells. The concentration of the target cells was
kept steady at 1,000 cells per plate, and the mix ratio of low:
high avidity T cells was gradually increased. Figure 2A shows
data of an experiment in which we observed strong specific lysis
of Me290 target cells even at the high concentration of a low
avidity T cell clone (ratio 8:1 of low:high avidity clones). In all the
concentrations of the low avidity clone, the differences remained
small, with overall high cytotoxicity in all conditions. Figure 2B
presents the compiled data of three independent experiments,
revealing similar results with only small differences (statistically
not significant) between the conditions with different ratios of
low and high avidity clones. In parallel, the Melan-A negative
melanoma target cell line Na8 was used as a positive and negative
control, in absence or presence of the native Melan-A peptide
(EAAGIGILTV; “EAA”), respectively. Specific lysis of Na8 target
cells was not reduced despite the addition of a low avidity clone
(Figure 2C). As expected, lysis was observed only in the presence
of the peptide.
The Presence of Low Avidity T Cells Does
Not Reduce the Cytokine Production by
High Avidity T Cells
To determine the cytokine production by the CD8T cell clones
with different functional avidities, we performed IFN-γ Elispot
assays, a well-suited method to compare T cell functions of
different clones alone, as well as after mixing them in defined
ratios (3). The maximum activity was determined when the
clones were plated alone (300 cells) and when mixing them in
different ratios (1:1 i.e., 150:150; and 1:2 i.e.,150:300; high:low
avidity clone). We observed that the high avidity clone 212
produced higher numbers of spots in comparison with the low
avidity clone. Similar to the findings in killing assays, the presence
of the low avidity clone 35 in the mixtures did not reduce the
function of the high avidity clone (Figure 3A). Similar results
were found with two different mixtures, namely with the ratios
of 150:150 and 150:300 of high:low avidity clones (Figure 3A).
Figure 3B shows the compiled results of three experiments,
revealing that the differences were statistically significant
between the low avidity clone and the other conditions, but no
differences between the high avidity clones and the mixtures. The
avidity of the clones used was re-verified by IFN-γ Elispot peptide
titration assays, confirming the avidity difference between high
and low avidity clones (Figure 3C and Table 1). As described
previously (3), the mixes of a high avidity clone with a low avidity
clone, at a 1:1 ratio (high: low), gave an intermediate EC50 value.
Mixing the clones at 1:2 (150 high: 300 low), the avidity was still
higher as compared to the low avidity clone alone.
The Presence of Low Avidity T Cells Does
Not Reduce the Anti-tumor Efficacy of
High Avidity T Cells in vivo
Following these in vitro experiments, we aimed to assess the
in vivo protective capacity of high and low avidity CD8T cells.
We used the model of immunodeficient NSG-HLA-A2 mice
that express a human HLA-A2 transgene (further referred to
as NSG-A2 mice) to perform adoptive T cell therapy using our
clones with defined avidity. Our aim was to assess whether the
presence of lower avidity T cells may inhibit the capacity of
high avidity T cells to inhibit melanoma growth in vivo. We
adoptively transferred mixtures of a low avidity T cell clone with
a high avidity T cell clone. Interestingly, melanoma growth was
similar in these mice as compared to mice transferred with only a
single T cell clone with high avidity (Figure 4A). Tumor growth
was more rapid in the mice that did not receive T cells, and in
mice that received only the low avidity T cells. This experiment
was repeated three times, each with similar results, showing
significantly reduced tumor growth in animals treated with the
high avidity clone and the mixture of high plus low avidity
clones, but not the low avidity clone (Figure 4B). Figure 4C
displays the IFN-γ Elispot peptide titration curves, showing the
functional avidity of the clones used for adoptive transfer to NSG-
A2 mice. Together, our results demonstrate that high avidity T
cells could inhibit melanoma growth in vivo, without reduction
of the therapeutic effect in the presence of low avidity T cells.
We conclude that the anti-tumor effect of adoptively transferred
T cells is not hampered by the co-presence of T cells with
lower avidity.
DISCUSSION
Antigen-specific T cell interactions play central roles in immunity
against microbes and cancers. The qualitative and quantitative
analysis of functional avidity of individual T cell clonotypes has
been important in understanding the cellular immune response
in health and disease (25). The sensitivity of a T cell to antigen
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FIGURE 2 | Pre-incubation of target cells with the low avidity T cell clones did not inhibit the cytotoxicity of the high avidity T cell clones. (A) At the constant
concentration of 1,000 target cells in every well, different numbers of low avidity T cells (clone 95) were pre-incubated for 1.5 h with Me290 melanoma target cells
(without synthetic peptide). Subsequently, the high avidity T cells (clone 214) was added in the following cell numbers (ratios) of low avidity clone: high avidity clone, at
80.000:10.000 (8:1), 40.000:10.000 (4:1), 20.000:10.000 (2:1), 10.000:10.000 (1:1), 5.000:10.000 (0.5:1), and incubated for further 3 h to determine specific lysis as
described in the methods section. (B) Average ± standard deviation of three independent assays. No statistically significant differences were detected (One-way
Anova). (C) Control experiment with the Melan-A negative melanoma cell line Na8, with and without the addition of synthetic Melan-A peptide (“EAA”; EAAGIGILTV) at
the concentration of 1µM, showing results that are representative for two experiments.
is influenced by multiple factors: the affinity of the TCR-
peptide-MHC interaction, and the engagement of multiple other
receptors on T cells and the density of these receptors on the T
cell surface within the T cell synapse (4, 26, 27).
Protection from infectious disease is more powerful if the
T cell response includes high avidity clones (28). Nevertheless,
T cell responses usually also include clones with lower avidity.
A too strong selection of particular (high avidity) clones may
result in too drastic narrowing of the CD8T cell repertoire that
would render the T cell response more vulnerable. Stochastic
recruitment/expansion seems more likely to maintain T cell
diversity, shown to be beneficial for instance in virus control
(29–31). Also in anti-tumoral T cell responses, generating and
maintaining a relatively large number of clonotypes may be more
powerful for both safeguarding the flexibility of the repertoire
and ensuring an effective immune response.
Our results revealed that low avidity CD8T cells do not inhibit
the function of high avidity CD8T cells in melanoma. For both
cytotoxicity and IFN-γ production, we did not find evidence
for inhibition or competition of low avidity T cells that would
reduce the interaction of high avidity T cells with peptide-MHC
complexes on the surface of tumor cells. Our findings are in
contrast to a previous report that low avidity T cells inhibited the
activity of high avidity T cells specific for tumor antigens (32).
There is increasing evidence that low avidity T cells do not hinder
their high avidity counterparts. A study by Zehn et al. showed
that even elevated numbers of low avidity memory T cells did not
inhibit the response of high avidity T cells (33). For our in vivo
analysis we used the model of immunodeficient NSG-A2 mice to
perform adoptive T cell therapy using our clones with defined
avidity. Our results show that also in vivo, the anti-tumor effect
of high avidity T cells is not hampered by the co-presence of T
cells with lower avidity.
While our in vitro experiments were limited to the interactions
of T cells with tumor cells, our in vivo analysis involved also
the many other components of the complexity of a complete
in vivo immune response, including human HLA-A2 expressing
antigen-presenting cells. However, humanized mice have the
limitation that certain molecular interactions may be altered or
absent due to species incompatibilities. Therefore, indirect effects
may have been missed, e.g., through modification of antigen
presenting cells. A second limitation of our study lies in the
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FIGURE 3 | IFN-γ production by T cell clones, alone and in mixed cultures of high and low avidity clones. (A) The high avidity clone produced higher spot numbers in
comparison to the low avidity clone. After mixing of the clones, plating half of the specific cells of the high avidity clone (150 cells), at ratios 1:1 and 1:2 with the low
avidity clone, the absolute total spot numbers were still higher than the single condition of the low avidity clone. (B) Compiled data of three experiments showing
statistically significant differences, One-way Anova, P-values ***<0.001; **<0.01; *<0.05. The T cell clones were analyzed by IFN-γ Elispot assays using T2 cells and
1µM of Melan-A peptide. (C) IFN-γ Elispot assay with titrated peptide concentrations for determining the functional avidity of the clones, alone and as mixtures; the
numeric values are shown in the small table.
fact that using T cell clones is a reductionist approach. In vivo
T cell responses are polyclonal, i.e., they usually involve more
than two clonotypes per epitope specificity. We made attempts
to overcome this limitation by studying clones representing
multiple clonotypes, in total comprising four high and four
low avidity clonotypes (Table 1). We have previously shown
that the natural in vivo polyclonal responses are relatively
well-represented by these clones that were derived from those
responses (3). Nevertheless, it should be taken into consideration
that our experiments only partially but not fully dissect the
complexity of natural polyclonal T cell competition.
High avidity T cells that react to tumor/self-proteins are
deleted in the thymus during T cell development, leaving
predominantly T cells with lower avidity for recognizing tumor
antigens. T cells are also regulated by peripheral tolerance
mechanisms, which further reduces the anti-tumor T cell
response (34). The avidity of neo-antigen specific T cells may
also be preferentially low, possibly because neo-antigens (closely)
resemble self-antigens that drive tolerance induction of high
avidity T cells. These considerations strengthen the notion that
low avidity T cells are abundant and are often generated in
immune responses, particularly in cancer patients. Negative
impacts of low avidity T cells to the immune response would have
unfavorable consequences on immunity. One could postulate
that low avidity T cells help to downregulate immune responses,
thus could act similarly as regulatory T cells. However, such a
model where low avidity T cells have immune regulatory roles
would require that these cells are controlled by mechanisms
that are distinct to the ones that control high avidity T cells.
To our knowledge there is no evidence for the existence of
such mechanisms.
It is obviously desirable that vaccines and immunotherapy
preferentially activate high avidity T cells, which are more
powerful than low avidity T cells. In parallel, a number of
strategies are being developed to improve the function of low
avidity T cells so that they may be used prophylactically or
therapeutically against cancer. Such strategies exploit the binding
properties of T cells to tumors both antigen-specifically and
non-specifically (35).
Melanoma tumors are often enriched in melanoma-reactive
TILs of both high and low avidity, whereby Melan-A-specific
T cells are frequently detectable among the melanoma-reactive
TILs in HLA-A2 positive patients (36). TILs are regularly used
for adoptive T cell therapy which can lead to clinical responses
in >50% of melanoma patients thus representing a potentially
powerful immunotherapy for metastatic cancer patients. Some
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FIGURE 4 | In vivo protective capacity of T cell clones in humanized mice. (A) 6 to 8 weeks old NSG-A2 mice (groups of 5 mice) were injected subcutaneously on the
right flank with 2 × 106 human Me275 melanoma cells. Once the Me275 tumors became palpable at around D23 post tumor engraftment, 1 × 106 of a high avidity T
cell clone (blue), a low avidity T cell clone (red) or a 1:1 mixture of the two clones (green) were injected intravenously in the tail vein. The results are from one of three
representative experiments. (B) Average ± standard deviation, and statistical comparisons (One-way Anova) of tumor volumes at the end of three repeat experiments,
substantiating the results in (A). P-values ***<0.001; **<0.01; *<0.05. (C) IFN-γ Elispot data from the clones used in vivo, showing the two distinct functional avidities.
strategies select TILs for adoptive transfer, whereas others do
not select but rather use the entire TIL population for treating
the melanoma patients. Selection does not appear to have a
significant impact on the clinical response rate, although this
subject requires further studies (37–41).
We conclude that low avidity T cells are likely present in
most immune responses and may not hamper their high avidity
counterparts. Further studies are necessary that carefully analyze
the protective power of T cells with defined functional avidity,
with the aim to clarify whether there are exceptions, i.e., whether
some low avidity T cells can indeed by harmful for patients in
need for protection against cancer.
MATERIALS AND METHODS
Patients
Twenty-nine HLA-A∗0201–positive patients with stage
III/IV metastatic melanoma received series of monthly
subcutaneous vaccinations with 0.1mg Melan-A/MART-
126−35 peptide and 0.5mg CpG 7909/PF-3512676 (Pfizer and
Coley Pharmaceutical Group), emulsified in IFA (Montanide
ISA-51; Seppic) in a phase I clinical trial (LUD 00-018,
ClinicalTrials.gov number NCT00112229, registered May 31,
2005). Eligibility criteria and study design were previously
described (42). The trial was conducted according to the
relevant regulatory standards, upon approval by Swissmedic
(the Swiss agency for therapeutic products), the Protocol
Review Committee of the Ludwig Institute for Cancer
Research New York and the Ethical Committee for Clinical
Research of the Faculty of Medicine of the University of
Lausanne. The latter also approved the experimental protocols
and the use of PBMC from healthy volunteers. Patients
were enrolled upon written informed consent. All methods
were carried out in accordance with relevant guidelines
and regulations.
Generation of CD8T Cell Clones
Blood withdrawal and handling, were performed as previously
described (3). Briefly, CD8+ cells were purified using MS
columns, loaded with a maximal number of 10 × 106 PBMCs
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labeled cells, using the MiniMACSTM separators attached to
the MACS MultiStand Magnet (Miltenyi). For generating T
cell clones, antigen-specific T cells were sorted directly ex vivo
with fluorescent MHC/peptide tetramers and CD8 mAb, using
a FACS Aria cell sorter (BD Biosciences). Sorted T cells were
cloned by plating at concentrations of respectively, 0.5 and 1
cell per well, in Terasaki plates, and stimulated with 1 × 106/ml
irradiated allogeneic PBMCs (feeder cells), PHA (1µg/ml), and
IL-2 (150 U/ml).
Chromium Release Cytotoxicity Assay
Chromium release assays were performed using radioactive
51-chromium. For experiments with titrated peptides, 51-
chromium-labeled TAP2/2-deficient T2 cells (HLA-A∗0201+)
were pulsed with serial dilutions from 10−6 M to 10−13 M of
Melan-A EAAGIGILTV peptide. For the assessment of tumor
cell killing, 1000 Me290 melanoma cells were 51-chromium-
labeled and used as target cells. A high avidity CD8T cell
clone alone, a low avidity clone alone, and a 1:1 mix of
them (half the amount from each) were tested side-by-side in
each experiment. The effector to melanoma cell ratios were
30:1, 10:1, 3:1, 1:1. In the mixtures, the ratio of high to
low avidity clones was always 1 to 1. For experiments with
variable low:high avidity T cell ratios shown in Figure 2, 1,000
target cells were plated in every well. Different numbers of
low avidity T cells were pre-incubated for 1.5 h with Me290
melanoma cells. The high avidity T cells were added in the
following cell numbers (ratios) of low avidity clone:high avidity
clone, at 80.000:10.000 (8:1), 40.000:10.000 (4:1), 20.000:10.000
(2:1), 10.000:10.000 (1:1), 5.000:10.000 (0.5:1), and incubated for
further 3 h to determine specific lysis. Control conditions were
performed with the Melan-A negative melanoma cell line Na8,
with and without the addition of synthetic Melan-A peptide
(“EAA”; EAAGIGILTV). After 4 h incubation, supernatants were
analyzed in a TopCount NXT benchtop microplate scintillation
and luminescence counter. To determine spontaneous and the
total 51-chromium release, medium or 1M HCL was added in
4 wells with target cells, respectively. The percentage of specific
lysis was calculated as 100 × (experimental – spontaneous
release)/(total – spontaneous release). All cytotoxicity assay
conditions were tested in duplicates, the average of the
two values is shown in the figures and was used for
data compilation.
IFN-γ Elispot Assay
Twenty-five microliter of 35% ethanol/well was put in 96 well
PVDF plates (MSIPS4510, Millipore) and incubated at room
temperature (RT) for 30 s. The wells were emptied by flicking
the plate over a sink and gently tapping on absorbent paper.
The plates were thoroughly washed 3x with 100 µl 1X PBS
per well. Hundred microliter of diluted capture antibody (100
µl into 10ml 1X PBS) was added to every well and the plates
were covered and incubated at 4◦C overnight. The wells were
washed as previously, once with 100 µl 1X PBS. Hundred
microliter of culture medium with 10% serum was added to
every well and the plates were incubated at RT for 2 h. The
wells were washed with 100 µl 1X PBS, and 300 antigen-specific
CD8T cells in 50 µl of RPMI with 8% Human serum were
plated with 50 µl of 20’000 T2 cells per well and the addition
of the native Melan-A peptide (EAA, stock 1 mg/ml) at the
indicated concentrations, in a total volume of 200 µl per well.
The plates were incubated at 37◦C in a CO2 incubator for 20 h.
The next day the plates were incubated with 100 µl of 0.05%
PBS-Tween solution (wash buffer) per well at 4◦C for 10min
and subsequently 3x with wash buffer. Hundred microliter of
diluted detection antibody (100 µl into 10ml Dilution buffer)
was added to every well and incubated at RT for 1 h 30min.
The plates were washed 3x with 100 µl of wash buffer and
100 µl of diluted Streptavidin –AP conjugate was added to
every well. After an incubation of 1 h at RT, the plates were
washed 3x with wash buffer and 3x with distilled water (both
sides of the membrane, peeling off the plate bottom). Hundred
microliter of BCIP/NBT buffer was added to every well and the
plates were incubated for 5–15min, monitoring spot formation
visually throughout the incubation period for sufficient color
development. The wells were emptied and both sides of the
membrane were rinsed 3x with distilled water. The frequency
of the resulting colored spots corresponding to the cytokine
producing cells was determined using the Elispot Bioreader
5000. The data were analyzed with Prism software as previously
described (3).
Mice and Adoptive Transfer of T Cell
Clones
The in vivo experiments were performed with immunodeficient
mice (NSG) transgenic for HLA.A2 [NOD.Cg-
PrkdcscidIl2rgtm1WjlTg(HLA-A2.1)1Enge/SzJ mice], referred
to as NSG-A2 mice in the text. The mice were purchased
from The Jackson Laboratory (Bar Harbor, ME) and then bred
in-house. All mice were maintained in specific pathogen free
conditions, given autoclaved food and water, and housed in
individually ventilated racks in the research animal facilities
of the Ludwig Cancer Research Center. Six to eight weeks old
NSG-A2mice (groups of five mice) were injected subcutaneously
on the right flank with 2 × 106 human Me275 melanoma cells.
Once the Me275 tumors became palpable at around D23 post
tumor engraftment, 1 × 106 of a high avidity T cell clone, a
low avidity T cell clone, or a 1:1 mixture of the two clones
were injected intravenously in the tail vein (100 µl PBS) of
mice. 45.000U IL-2 was injected subcutaneously for the first
2 days. The tumor length and width were measured every 2
days, using a caliper, and the tumor volume was calculated using
the formula V = (L × W × W)/2, where V is tumor volume,
W is the tumor width and L the tumor length. All animal
experiments were conducted in accordance with guidelines of
the Animal Care and Use Committee of the Swiss Law and under
animal protocols approved by the Veterinary Service of the
Canton Vaud.
DATA AVAILABILITY
All datasets generated for this study are included in the
manuscript/supplementary files.
Frontiers in Immunology | www.frontiersin.org 7 September 2019 | Volume 10 | Article 2115
Ioannidou et al. T Cell Responses in Melanoma
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Ethical Committee for Clinical Research
of the Faculty of Medicine of the University of Lausanne.
The patients/participants provided their written informed
consent to participate in this study. The animal study
was reviewed and approved by Committee of the
Swiss Law for Animal Care and Use, University of
Lausanne, Switzerland.
AUTHOR CONTRIBUTIONS
KI, DV, and DS: conception and design. KI, OR, and
AS: acquisition of data. KI, DV, and DS: analysis
and interpretation of data. KI, HM-E, DV, and DS:
writing, review, and revision of manuscript. KI, PB, and
DV: technical and material support. PB, DV, and DS:
study supervision.
FUNDING
This project was supported by the Swiss Cancer Research
(KFS-3971-08-2016), the Swiss National Science Foundation
(310030-179459, CRSII3-160708), Alfred and Annemarie von
Sick, Switzerland, the University of Lausanne, Switzerland, and
the Cancer Research Institute, USA.
ACKNOWLEDGMENTS
We thank the patients and healthy blood donors for their
dedicated collaboration. The authors gratefully acknowledge
Nicole Montandon for sample processing, and the members of
the DS, DV, and Verdeil groups for multifold support.
REFERENCES
1. Dustin ML, Chakraborty AK, Shaw AS. Understanding the structure and
function of the immunological synapse. Cold Spring Harb Perspect Biol. (2010)
2:a002311. doi: 10.1101/cshperspect.a002311
2. Dustin ML, Choudhuri K. Signaling and polarized communication across the
T cell immunological synapse. Annu Rev Cell Dev Biol. (2016) 32:303–25.
doi: 10.1146/annurev-cellbio-100814-125330
3. Ioannidou K, Baumgaertner P, Gannon PO, Speiser MF, Allard M, Hebeisen
M, et al. Heterogeneity assessment of functional T cell avidity. Sci Rep. (2017)
7:44320. doi: 10.1038/srep44320
4. Viganò S, Utzschneider DT, Perreau M, Pantaleo G, Zehn D, Harari A.
Functional avidity: a measure to predict the efficacy of effector T cells? Clin
Dev Immunol. (2012) 2012:153863. doi: 10.1155/2012/153863
5. Hesse MD, Karulin AY, Boehm BO, Lehmann PV, Tary-Lehmann M. A T
cell clone’s avidity is a function of its activation state. J Immunol. (2001)
167:1353–61. doi: 10.4049/jimmunol.167.3.1353
6. Hanson J, Sundararaman S, Caspell R, Karacsony E, Karulin AY, Lehmann
PV. ELISPOT assays in 384-well format: up to 30 data points with one million
cells. Cells. (2015) 4:71–83. doi: 10.3390/cells4010071
7. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion
of high- or low-avidity cytotoxic T lymphocytes and efficacy for
adoptive immunotherapy. Proc Natl Acad Sci USA. (1996) 93:4102–7.
doi: 10.1073/pnas.93.9.4102
8. Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi
D, et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-
specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res.
(2001) 61:5850–6.
9. Bullock TN, Mullins DW, Colella TA, Engelhard VH. Manipulation of
avidity to improve effectiveness of adoptively transferred CD8(+) T cells
for melanoma immunotherapy in human MHC class I-transgenic mice. J
Immunol. (2001) 167:5824–31. doi: 10.4049/jimmunol.167.10.5824
10. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell
transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer.
(2008) 8:299–308. doi: 10.1038/nrc2355
11. Mallone R, Kochik SA, Reijonen H, Carson B, Ziegler SF, Kwok WW, et al.
Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood.
(2005) 106:2798–805. doi: 10.1182/blood-2004-12-4848
12. Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Loss of CTL function
among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Cancer Res. (2008) 68:2993–3000. doi: 10.1158/0008-5472.CAN-07-5008
13. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for
cancer: harnessing the T cell response. Nat Rev Immunol. (2012) 12:269–81.
doi: 10.1038/nri3191
14. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive
T cell therapy using antigen-specific CD8+ T cell clones for the treatment
of patients with metastatic melanoma: in vivo persistence, migration, and
antitumor effect of transferred T cells. Proc Natl Acad Sci USA. (2002)
99:16168–73. doi: 10.1073/pnas.242600099
15. Rosenberg SA, Yang JC, Sherry RM, Kammula US, HughesMS, PhanGQ, et al.
Durable complete responses in heavily pretreated patients with metastatic
melanoma using T-cell transfer immunotherapy. Clin Cancer Res. (2011)
17:4550–7. doi: 10.1158/1078-0432.CCR-11-0116
16. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J,
et al. Specific lymphocyte subsets predict response to adoptive cell
therapy using expanded autologous tumor-infiltrating lymphocytes in
metastatic melanoma patients. Clin Cancer Res. (2012) 18:6758–70.
doi: 10.1158/1078-0432.CCR-12-1177
17. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy
D, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients
with metastatic melanoma: intent-to-treat analysis and efficacy after
failure to prior immunotherapies. Clin Cancer Res. (2013) 19:4792–800.
doi: 10.1158/1078-0432.CCR-13-0380
18. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity
melanoma-reactive CTL from heterogeneous populations using peptide-
MHC tetramers. J Immunol. (1999) 162:2227–34.
19. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High
avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo
antitumor efficacy. J Immunol. (1999) 162:989–94.
20. Sadelain M, Riviere I, Brentjens R. Targeting tumours with
genetically enhanced T lymphocytes. Nat Rev Cancer. (2003) 3:35–45.
doi: 10.1038/nrc971
21. Murphy A, Westwood JA, Teng MW, Moeller M, Darcy PK, Kershaw MH.
Gene modification strategies to induce tumor immunity. Immunity. (2005)
22:403–14. doi: 10.1016/j.immuni.2005.03.007
22. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry
RM, et al. Cancer regression in patients after transfer of genetically
engineered lymphocytes. Science. (2006) 314:126–9. doi: 10.1126/science.11
29003
23. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley
ME, et al. Tumor regression in patients with metastatic synovial cell
sarcoma and melanoma using genetically engineered lymphocytes reactive
with NY-ESO-1. J Clin Oncol. (2011) 29:917–24. doi: 10.1200/JCO.2010.3
2.2537
24. Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, et al.
New generation vaccine induces effective melanoma-specific CD8+ T cells
in the circulation but not in the tumor site. J Immunol. (2006) 177:1670–8.
doi: 10.4049/jimmunol.177.3.1670
Frontiers in Immunology | www.frontiersin.org 8 September 2019 | Volume 10 | Article 2115
Ioannidou et al. T Cell Responses in Melanoma
25. Tomaru U, Yamano Y, Nagai M, Maric D, Kaumaya PT, Biddison W, et al.
Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition
of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in
chronic viral infections. Nat Med. (2003) 9:469–76. doi: 10.1038/nm845
26. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, et al. Ex
vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med.
(2003) 9:1377–82. doi: 10.1038/nm942
27. von Essen MR, Kongsbak M, Geisler C, Mechanisms behind functional
avidity maturation in T cells. Clin Dev Immunol. (2012) 2012:163453.
doi: 10.1155/2012/163453
28. Cukalac T, Chadderton J, Handel A, Doherty PC, Turner SJ, Thomas PG,
et al. Reproducible selection of high avidity CD8+ T-cell clones following
secondary acute virus infection. Proc Natl Acad Sci USA. (2014) 111:1485–90.
doi: 10.1073/pnas.1323736111
29. Williams MA, Bevan MJ. Effector and memory CTL
differentiation. Annu Rev Immunol. (2007) 25:171–92.
doi: 10.1146/annurev.immunol.25.022106.141548
30. Cornberg M, Chen AT, Wilkinson LA, BrehmMA, Kim SK, Calcagno C, et al.
Narrowed TCR repertoire and viral escape as a consequence of heterologous
immunity. J Clin Invest. (2006) 116:1443–56. doi: 10.1172/JCI27804
31. Belz GT, Xie W, Altman JD, Doherty PC. A previously unrecognized H-
2D(b)-restricted peptide prominent in the primary influenza A virus-specific
CD8(+) T-cell response is much less apparent following secondary challenge.
J Virol. (2000) 74:3486–93. doi: 10.1128/JVI.74.8.3486-3493.2000
32. Chung B, Stuge TB, Murad JP, Beilhack G, Andersen E, Armstrong
BD, et al. Antigen-specific inhibition of high-avidity T cell target lysis
by low-avidity T cells via trogocytosis. Cell Rep. (2014) 8:871–82.
doi: 10.1016/j.celrep.2014.06.052
33. Zehn D, Turner MJ, Lefrançois L, Bevan MJ. Lack of original antigenic
sin in recall CD8(+) T cell responses. J Immunol. (2010) 184:6320–6.
doi: 10.4049/jimmunol.1000149
34. Hurwitz AA, Cuss SM, Stagliano KE, Zhu Z. T cell avidity and tumor
immunity: problems and solutions. Cancer Microenviron. (2014) 7:1–9.
doi: 10.1007/s12307-013-0143-1
35. McMahan RH, Slansky JE. Mobilizing the low-avidity T cell
repertoire to kill tumors. Semin Cancer Biol. (2007) 17:317–29.
doi: 10.1016/j.semcancer.2007.06.006
36. Bobinet M, Vignard V, Rogel A, Khammari A, Dreno B, Lang F, et al.
MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized
by Th1 CD4+ T cells from melanoma patients. PLoS ONE. (2012) 7:e51716.
doi: 10.1371/journal.pone.0051716
37. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ,
et al. Adoptive T-cell therapy using autologous tumor-infiltrating
lymphocytes for metastatic melanoma: current status and future
outlook. Cancer J. (2012) 18:160–75. doi: 10.1097/PPO.0b013e3182
4d4465
38. Ullenhag GJ, Sadeghi AM, Carlsson B, Ahlström H, Mosavi F, Wagenius
G, et al. Adoptive T-cell therapy for malignant melanoma patients
with TILs obtained by ultrasound-guided needle biopsy. Cancer
Immunol Immunother. (2012) 61:725–32. doi: 10.1007/s00262-011-
1182-4
39. Saint-Jean M, Knol AC, Volteau C, Quéreux G, Peuvrel L, Brocard
A, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes
in advanced melanoma patients. J Immunol Res. (2018) 2018:3530148.
doi: 10.1155/2018/3530148
40. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation
of tumor-infiltrating lymphocyte cultures for use in adoptive transfer
therapy for melanoma patients. J Immunother. (2003) 26:332–42.
doi: 10.1097/00002371-200307000-00005
41. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment
of patients with cancer. Nat Rev Cancer. (2003) 3:666–75. doi: 10.1038/
nrc1167
42. Baumgaertner P, Jandus C, Rivals JP, Derré L, Lövgren T, Baitsch L, et al.
Vaccination-induced functional competence of circulating human tumor-
specific CD8 T-cells. Int J Cancer. (2012) 130:2607–17. doi: 10.1002/ijc.26297
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Ioannidou, Randin, Semilietof, Maby-El Hajjami, Baumgaertner,
Vanhecke and Speiser. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 9 September 2019 | Volume 10 | Article 2115
